(HealthDay)—The U.S. Food and Drug Administration has approved a new drug for chronic hepatitis C infection that some experts hope will cut down on side effects from current therapies.
Nov 25, 2013
0
0
Advances in treatment for human immunodeficiency virus (HIV) have made it possible for people with HIV to survive much longer. As they age, however, many experience impaired thinking, memory loss, mood swings and other evidence ...
Dec 11, 2014
0
0
Treating chronic hepatitis C infection with antiviral drugs could halve the risk of developing the most common form of liver cancer, in some cases, indicates an analysis of the published research in one of the new BMJ Open ...
Oct 22, 2012
0
0
More than one in nine people with hepatitis C in Canada spend time in a correctional facility each year and researchers said this presents a unique opportunity to focus hepatitis C prevention and control efforts in incarcerated ...
Dec 17, 2015
0
3
A study of patients infected with acute hepatitis C virus (HCV) infection found that women had higher rates of spontaneous viral clearance—undetectable levels of the virus without initiating drug therapy. Findings published ...
Sep 12, 2013
0
0
A monoclonal antibody developed by MassBiologics of the University of Massachusetts Medical School (UMMS) and tested in an animal model at the Texas Biomedical Research Institute, prevents infection by the hepatitis C virus ...
Aug 30, 2012
0
0
University of Adelaide researchers are investigating how the liver responds to hepatitis C virus (HCV) and why some people can control the virus while others can't. The aim is to find better therapies to combat hepatitis ...
Jul 26, 2013
0
0
New, highly curative hepatitis C therapy is both safe and effective as a treatment option for people who inject drugs receiving opioid substitution therapy according to the results of a world-first clinical trial led by Professor ...
Aug 9, 2016
0
5
By studying individuals who spontaneously clear hepatitis C infections, a team of researchers has identified viable vaccine targets for a disease that infects 70 million worldwide with case numbers increasing every year.
Mar 25, 2024
0
41
A study by researchers from Los Alamos National Laboratory and a multinational team reveals how daclatasvir, a direct-acting antiviral agent in development for the treatment of hepatitis C virus (HCV), targets one of its ...
Feb 18, 2013
0
0
